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Abstract
Background: The ‘phosphate-binding tag’ (phos-tag) reagent enables separation of phospho-proteins during SDS-PAGE by
impeding migration proportional to their phosphorylation stoichiometry. Western blotting can then be used to detect and
quantify the bands corresponding to the phospho-states of a target protein. We present a method for quantification of data
regarding phospho-states derived from phos-tag SDS-PAGE. The method incorporates corrections for lane-to-lane loading
variability and for the effects of drug vehicles thus enabling the comparison of multiple treatments by using the untreated
cellular set-point as a reference. This method is exemplified by quantifying the phosphorylation of myosin regulatory light
chain (RLC) in cultured human uterine myocytes.
Methodology/Principal Findings: We have evaluated and validated the concept that, when using an antibody (Ab) against
the total-protein, the sum of all phosphorylation states in a single lane represents a ‘closed system’ since all possible
phospho-states and phosphoisotypes are detected. Using this approach, we demonstrate that oxytocin (OT) and calpeptin
(Calp) induce RLC kinase (MLCK)- and rho-kinase (ROK)-dependent enhancements in phosphorylation of RLC at T18 and S19.
Treatment of myocytes with a phorbol ester (PMA) induced phosphorylation of S1-RLC, which caused a mobility shift in the
phos-tag matrices distinct from phosphorylation at S19.
Conclusion/Significance: We have presented a method for analysis of phospho-state data that facilitates quantitative
comparison to a reference control without the use of a traditional ‘loading’ or ‘reference’ standard. This analysis is useful for
assessing effects of putative agonists and antagonists where all phospho-states are represented in control and experimental
samples. We also demonstrated that phosphorylation of RLC at S1 is inducible in intact uterine myocytes, though the signal
in the resting samples was not sufficiently abundant to allow quantification by the approach used here.
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Introduction
The cellular responses mediated by protein phosphorylation are
vast in number and function [1], and therefore a variety of
biochemical techniques has been developed to study this important
cell signaling modality [2]. Among these, western immunoblotting
(WB) is the most widely utilized for the routine measurement of
phospho-proteins in experimental samples after 1-dimensional
sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-
PAGE). The power and utility of this technique has recently been
strengthened by the development of a dinuclear metal complex
‘phosphate-binding tag’ (phos-tag) that can be incorporated into the
polyacrylamide gel matrix prior to SDS-PAGE [3,4]. This
modification of traditional SDS-PAGE, promotes a physical
separation of phospho-proteins proportional to the phosphorylation
stoichiometry. Thus a single protein might separate into multiple
bands, each corresponding to a different phospho-state (forms of a
protein containing the same number of phospho-modifications).
In traditional phospho-protein analyses by WB, the signal
derived from a phospho-specific antibody (Ab) toward the target
protein is normalized to a reference protein, or to the ‘total’ (‘bulk’)
target protein using an Ab that does not discriminate between
phosphorylated and non-phosphorylated forms. This type of
analysis is normally limited to measuring changes at a single
phospho-site per assay. In contrast, Mn
2+-phos-tag SDS-PAGE
permits the study of the effects of experimental treatments on the
target protein across its various phospho-states by probing replica
membrane with an anti-total-target protein Ab and enables the
study of protein phosphorylation in the absence of phospho-
protein-specific Abs. Where phospho-protein-specific Abs are
available, the technique yields information regarding the distribu-
tion of specific phosphoisotypes (i.e. identical phosphorylation
sites) across various phospho-states (i.e. equivalent phosphorylation
stoichiometries). As such, this technique permits identification of
the phospho-states corresponding to specific phosphoisotypes. A
previous report using Mn
2+-phos-tag SDS-PAGE to assess
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strated the enhanced sensitivity of the technique [5]. Others have
focused principally on discovery of novel phospho-states, or
quantifications of single phospho-states or phosphoisotypes [6–8].
We have used this methodology to validate the phospho-specificity
of Abs directed toward RLC in lysates derived from primary
cultures of human uterine myocytes [9]. Here we quantified the
changes in the phospho-states of RLC, by employing a method
that does not rely on a ‘loading control’ protein, and produces
vehicle-corrected data that are expressed relative to the untreated
distribution to enable a direct comparison between drugs with
different vehicles.
As an exemplary model, we have measured the phospho-state
distribution of RLC in human uterine myocyte lysates under
various experimental conditions. The contractility of uterine and
other smooth muscle (SM) beds is dependent on the state of
phosphorylation of RLC. In particular, phosphorylation of RLC at
S19 triggers cell shortening and force production at the tissue level
[10–14]. The primary enzyme implicated in phosphorylation of
RLC at S19 is myosin RLC kinase (MLCK) [15]. The resultant
phospho-S19-RLC (p19RLC), through an unknown mechanism,
is associated with activation of the myosin heavy chain ATPase,
which provides energy for the power stroke. Subsequent
phosphorylation of T18, resulting in T18/S19-diphospho-RLC
(p18p19RLC) causes enhanced activation of the myosin ATPase
[16,17]. Production of p18p19RLC might therefore be of
significant importance for SM force production. This potentially
important distinction between mono- (S19) and di-phosphorylated
(T18/S19) proteins exemplifies the utility of a relatively simple
approach to assess phospho-state changes following experimental
perturbations.
A potential complication in this phospho-RLC analysis is that a
single phospho-state could contain more than one phosphoisotype.
Similarly, one phospho-site might appear in more than one
phospho-state [18–20]. Therefore, the goals of this study were to 1)
develop a method for quantification of phospho-state distribution
data, 2) evaluate and validate this method under various treatment
conditions, and 3) evaluate whether the reported changes in
phosphorylation of RLC result from activity at T18 and S19 alone,
or whether they might be explained by activity at other
phosphorylation sites. The scheme for data analyses provided
here represents a novel method for evaluating phosphorylation
reactions that might yield significant insight into the integration of
cellular signals at the level of the target protein.
Results and Discussion
Detection of Myosin Regulatory Light Chain Phospho-
states in Uterine Myocyte Lysates
Several studies have shown that three distinct phospho-states of
RLC are detectable in SM preparations [5,18–25]. These three
phosphoisotypes most likely correspond to unphosphorylated,
mono-phosphorylated (S19), and diphosphorylated (T18/S19)
RLC. To ensure preservation of phospho-modifications during
cell lysis, we harvested total cellular proteins by trichloroacetate
precipitation (see methods). After traditional SDS-PAGE separa-
tion, Abs directed toward the C-terminus of total-RLC (CtRLC,
no phospho-specificity), phospho-S19-RLC (p19RLC), and phos-
pho-T18/S19-RLC (p18p19RLC) recognize only a single band of
20 kDa on WB replica membranes (Figure 1A). In contrast, when
uterine myocyte protein lysates are separated by Mn
2+-phos-tag
SDS-PAGE these three Abs yield distinct banding patterns. The
CtRLC Ab (Figure 1B) produces three distinct bands in lysates
from unstimulated uterine myocytes. These data do not provide
information regarding the phosphoisotypes contained within each
band. Thus, we have chosen ‘0pRLC’, ‘1pRLC’, and ‘2pRLC’ as
the terminology to emphasize phosphorylation stoichiometry
irrespective of the phosphoisotypes represented.
The p19RLC Ab detects two phospho-RLC phospho-states and
does not detect the 0pRLC state. For clarity, we have used
‘0pRLC
T’, ‘1pRLC
T’, and ‘2pRLC
T’ to denote measurements
obtained by the CtRLC Ab, and the notation ‘1pRLC
19’ and
‘2pRLC
19’ for those reported by the p19RLC Ab. To verify that
the upper of these three bands corresponds to 2pRLC, we probed
a replica membrane with an anti-p18p19RLC Ab.
Rationale and Experimental Approach for Parallel
Quantification of RLC Phospho-states
In order to quantify these three phospho-states across various
treatment groups, we have considered that the bands in each lane
detected by the CtRLC Ab represent a ‘closed system’, such that
an enhancement of one of the three phospho-states must be
reflected by an equivalent diminution of one (or both) of the
others, and vice versa. Use of this ‘closed system’ concept has
several advantages that will be discussed in a later section that will
address its validation.
To demonstrate quantifiable changes in the phospho-state
distribution of RLC, we treated primary cultures of uterine
myocytes with pharmacological agents likely to alter to alter
phosphorylation of RLC. RhoA and rho-kinase (ROK) are known
to regulate uterine contractility [26–30]. Specifically, rhoA-ROK
activation reduces RLC phosphatase (MLCP) activity, and
Figure 1. Demonstration of RLC phospho-states in human
uterine myocyte lysates. A. WBs produced by separation of proteins
in lysates from unstimulated uterine myocytes by traditional SDS-PAGE.
Single lanes were loaded with ,25 mg of protein/lane. Abs directed
against the C- terminus of total-RLC (CtRLC), phospho-S19-RLC
(p19RLC), and diphospho-T18/S19-RLC (p18p19RLC) identify a single
prominent band of 20 kDa. B. WBs produced after Mn
2+-phos-tag SDS-
PAGE. CtRLC, p19RLC, and p18p19RLC Abs identified three, two, and
one specific band(s), respectively. The lower, middle, and upper bands
in these blots correspond to non-, mono-, and di-phosphorylated RLC,
denoted as 0pRLC, 1pRLC, and 2pRLC.
doi:10.1371/journal.pone.0020903.g001
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manipulate this pathway pharmacologically, cells were treated
with glycyl-H-1152 (g-H, rho-kinase inhibitor) and calpeptin
(Calp, rhoA activator). We also treated uterine myocytes with
oxytocin (OT), which is the most potent physiological stimulant for
this cell type.
Calp has been shown to specifically activate rhoA in fibroblasts
cultures, possibly by influencing a protein tyrosine-phosphatase
upstream of rhoA [31,32]. To confirm that Calp increases rhoA
activation in uterine myocytes, we quantified the GTP-bound
‘active’ rhoA from myocytes treated with Calp. Figure 2A confirms
that Calp (0.5 mU/mL, 15 min) induces rhoA activation
(2.4360.43 fold of vehicle, n=2) in cultured uterine myocytes.
Further, we evaluated whether rhoA activation by Calp was
associated with increased phosphorylation of RLC by the in-cell
western technique (see methods). Figure 2B shows that Calp
strongly induces diphosphorylation of RLC in comparison to
monophosphorylation. The Calp-induced enhancement in dipho-
sphorylated RLC can be attenuated by using a rhoA inhibitor (C3
transferase), again confirming that Calp activates rhoA. The cell-
permeable ROK inhibitor g-H (1 mM, 30 min) was selected due to
its high potency and selectivity for its target relative to other
commercially available pharmacologic inhibitors [33–35]. We
have previously demonstrated the optimal time course and
concentrations for OT in this experimental system [9].
Quantification of Phospho-state Distributions
This analysis has two primary goals: 1) isolating the effect of the
treatment of interest from any vehicle-induced change in the
phospho-state distribution, and 2) facilitating comparisons across
treatmentsby expressingthem relative to a common referencepoint
(untreated distribution). Figure 3A shows representative WBs
obtained for the treatment groups described. Distribution data
were obtained by expressing the signal integrated intensity at each
band position as a fraction of their sum total (e.g. [signal 0pRLC
T]/
([signal 0pRLC
T]+[signal 1pRLC
T]+[signal 2pRLC
T]), etc.), and
averagingthese proportions for n=5–8 samples. This ‘sum method’
amounts to performing an ‘in-lane’ normalization, in place of that
commonly achieved by using a loading control. We propose that
this ‘in-lane normalization’ method has several advantages that are
discussed in a subsequent section. Note that the WBs have been
intensified for all figures so that all three bands are visible, where
possible. This is achieved by restricting the upper and lower
boundaries of pixel intensity that are shown by the quantification
software. The quantitative estimates of band intensity are
completelyindependentofthesemanipulations.Theblotspresented
here did not exhibit pixel saturation, and therefore have not
exceeded the upper limit of the scanner in detecting higher protein
loads.
Figure 3B demonstrates the raw phospho-RLC proportional
distributions measured by the CtRLC Ab. In the untreated
distribution (n=12), approximately 4764% of the RLC pool is
represented by 0pRLC
T,3 6 62% by 1pRLC
T, and 1663% by
2pRLC
T. Next, we corrected for the effects of the vehicles by
subtracting the vehicle-induced changes from those of the
corresponding treatments. The net treatment-induced changes
are presented in Figure 3C and these data were used to calculate
the effect of each treatment relative to the untreated distribution in
Figure 3D. This provides a common reference and enables
comparisons across treatments (for numerical data, see Table 1).
Relative to the untreated distribution, g-H (n=5) promotes
significant reduction in phospho-RLC, as evidenced an enhance-
ment in the proportion of 0pRLC
T to 8662% from 4764% in
untreated samples, whereas 1pRLC
T and 2pRLC
T fell to 762%
and 662% respectively. Calp (n=8) treatment causes a specific
increase in 2pRLC
T from 1663% to 3868%, in agreement with
the increase in p18p19RLC shown in Figure 2. This enhancement
in 2pRLC
T is accompanied by a corresponding reduction in
0pRLC
T from 4764% to 2966%, but no change in 1pRLC
T
(from 3662% to 3464%). These finding suggest that activation of
rhoA, and presumably ROK, is associated with a specific increase
in the intracellular concentrations of diphosphorylated RLC. OT
appears to enhance both 1pRLC
T and 2pRLC
T, perhaps
favouring the former (final proportions of 54611% and
36610%, respectively).
The data shown in Figure 3C illustrate that significant
quantitative differences might result from the omission of a vehicle
correction step. In particular for OT, the 2pRLC
T state appears to
Figure 2. Validation of increased rhoA activity and phosphorylation of RLC by calpeptin. A. Estimation of GTP-bound ‘active’ rhoA in
uterine myocytes treated with Calp or vehicle (DMF) for 15 min (n=2). RhoA content was quantified relative to a-actin loading control, and used to
correct rhoA activity data. Error bars represent standard deviations. B. Quantification of pRLC and ppRLC in uterine myocytes treated with Calp and
with increasing concentrations of a cell-permeable rhoA inhibitor (C3 transferase) by ICW (n=4). * and ** indicate significant differences from vehicle
or Calp alone (second histogram), respectively. Calp (calpeptin); rhoA activator (0.5 mU/mL). p,0.05 in all cases as determined by one-way ANOVA
followed by Tukey test.
doi:10.1371/journal.pone.0020903.g002
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mechanical stimulation of cells by pipetting the treatment solution.
The short duration of treatment (20 sec) prevents this stimulatory
effect from returning to basal levels. Importantly, the OT vehicle
does not reduce 0pRLC
T as OT does (Figure 3B and C). Thus,
ignoring the effect of the OT vehicle underestimates the true
extent of phosphorylation of RLC induced by OT.
In summary, these data are normalized in three successive ways:
1) in-lane normalized to correct for variations in protein loading
and signal intensity, 2) vehicle normalized to ascertain that the
measured effect can be attributed to the drug or treatment of
interest, and 3) normalized to the untreated distribution to permit
comparisons across treatments.
Validation of the ‘Closed-System’ Concept
The method for data normalization of a closed system described
above has advantages over normalization to an in-lane loading
control. Specifically, the use of a traditional loading control might
not be feasible in Mn
2+-phos-tag acrylamide gels for several
reasons. First, the physical separation of phospho-states along the
vertical dimension of the gels increases the likelihood that the
loading control protein overlaps with a band corresponding to the
protein of interest. Second, if it is phosphorylated, the loading
control protein might dissociate into two or more bands and might
complicate identification and quantification of loading control and
the protein of interest on the same blot. Despite these potential
problems, to validate the ‘closed system’ concept we performed a
traditional loading control quantification of the phospho-states
detected by the CtRLC Ab using SM a-actin as our in-lane
reference.
Figure 4A demonstrates that the a-actin signal remains localized
to a single position after traditional and Mn
2+-phos-tag SDS-
PAGE separation without any evidence of phosphorylation under
our experimental conditions. Though we were fortunate to have
chosen a-actin, finding a loading control protein that does not
suffer from at lease one of the above-mentioned problems might
prove difficult. If a single-channel detection method is used, WB
quantification might be unfeasible. Where dual-channel detection
is used for segregating the loading control and target protein
signals, the primary-Ab-secondary-Ab-fluorophore combinations
Figure 3. Quantification of RLC phospho-state distribution.
Panels A-D correspond to WB data derived using an Ab directed toward
the C-terminus of RLC. A. Representative WBs demonstrating RLC
phospho-states separated by Mn
2+-phos-tag SDS-PAGE. Uterine myo-
cytes were lysed and total protein was harvested after the following
treatments: untreated, or treated with g-H, Calp, OT, or with their
corresponding vehicles. B. Quantification of bands identified in panel A
(untreated; n=12, g-H; n=5, Calp; n=8, OT; n=7). The signals derived
from 0pRLC
T, 1pRLC
T, and 2pRLC
T are expressed as the proportion of
their sum total within each lane. C. Absolute magnitude of the
difference in each phospho-state caused by the treatments in
comparison to the corresponding vehicle (‘+’ indicates enhancement
relative to vehicle, ‘2’ indicates diminution relative to vehicle).
D. Vehicle-corrected distribution data obtained by combining the data
in panel C to the untreated group distribution. g-H (glycyl-H-1152); ROK
inhibitor (1 mM). Calp (calpeptin); rhoA activator (0.5 mU/mL). OT;
oxytocin (100 nM). All data are shown as means 6 SEMs. The
corresponding numerical data are compiled in Table 1.
doi:10.1371/journal.pone.0020903.g003
Table 1. Changes in Phosphorylated RLC Proportions in
uterine myocytes.
% of total RLC
N 0pRLC 1pRLC 2pRLC
Untreated 12 47643 6 621 6 63
g-H (1 mM) 5 8662* 762** 662***
OT (100 nM) 7 1062* 54611 36610***
OT+g-H 4 1967* 8068** 161***
OT+ML7 (25 mM) 4 2068* 6664** 1466
OT+ML7+g-H 4 40645 1 66** 962
Calp (0.5 mU/mL) 8 2966* 34643 8 68***
Calp+g-H 3 76612* 33615 060***
Calp+ML7 3 37633 7 632 6 60
Calp+ML7+g-H 2 40603 4 622 6 61
All data are shown as mean 6 SEM.
*, **, and ***indicate significant differences (p,0.05) compared to 0pRLC,
1pRLC and 2pRLC in the untreated group, respectively.
doi:10.1371/journal.pone.0020903.t001
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system’ method for data quantification proposed here circumvents
all of these difficulties by eliminating the need for measuring a
loading control protein.
For this validation, the signals for 0pRLC
T, 1pRLC
T, and
2pRLC
T in the vehicle and treatment lanes were normalized
individually to the in-lane a-actin signal, without expressing them
as the proportions of the sum-total of signals as was performed to
obtain Figure 3B. The a-actin-normalized fold-changes relative to
vehicle are shown in Figure 4C. Qualitatively, these data are in
agreement with those in Figure 3D. ROK inhibition with g-H
promotes an increase in 0pRLC
T relative to 1pRLC
T and
2pRLC
T. RhoA activation with Calp causes a large increase in
2pRLC
T. OT treatment causes an enhancement of both 1pRLC
T
and 2pRLC
T that is reflected as a dramatic reduction in 0pRLC
T.
To provide a direct quantitative comparison between the
Figure 4C and the in-lane sum method above, we computed the
fold changes in the proportion of 0pRLC
T, 1pRLC
T, and
2pRLC
T in the treatment groups relative to their proportions in
the vehicle groups. No significant differences between the ‘closed
system’ (‘sum method’) and the traditional loading control
methods were observed. Both methods show that g-H treatment
causes an increase in 0pRLC
T (sum method: 1.7960.05, a-actin:
2.2860.69 fold of vehicle), and a reduction in 1pRLC
T (sum
method: 0.2060.05, a-actin: 0.2760.05) and 2pRLC
T (sum
method: 0.2660.07, a-actin: 0.2860.09). Calp causes increased
2pRLC
T (sum method: 2.1360.40, a-actin: 1.9960.06). OT
causes virtually complete phosphorylation of the pool of RLC, as
evidenced by near abolition of 0pRLC
T (sum method: 0.1660.02,
a-actin: 0.0960.03) and an increase in 1pRLC
T (sum method:
2.1360.40, a-actin: 1.9560.55) and 2pRLC
T (sum method:
1.4760.18, a-actin: 1.7460.82). The remarkable agreement
between these a-actin normalized data and those in Figure 3D
for these measurements demonstrate that the in-lane normaliza-
tions performed for the data in Figure 3 provide similar
information to traditional loading controls.
Analysis of p19RLC Phosphoisotype Distribution
We next focused attention on the phosphoisotype composition
of each of the phospho-states following Mn
2+-phos-tag separation.
In preliminary experiments, we validated the specificity of two
anti-phospho-S19-RLC Abs by WB after Mn
2+-phos-tag SDS-
PAGE separation (Figure 5A). These Abs were derived from mice
(monoclonal – ‘p19RLC (MMAb)’), or rabbits (polyclonal –
‘p19RLC (RPAb)’). The p19RLC (MMAb) was unable to detect
the 2pRLC band present in blots probed with the CtRLC Ab and
the p19RLC (RPAb). The most likely explanation for this finding
is obstructed binding of the Ab in the presence of phospho-T18-
RLC. Still, this Ab was useful for quantifying monophosphoryla-
tion of RLC specifically, as was demonstrated in Figure 2. Anti-
total-protein Abs might also suffer from obstructed binding. Here,
we selected the CtRLC Ab on the basis of published evidence
suggesting phosphorylation of RLC at sites concentrated in the
first 20 amino acids of the N-terminal region and the possibility of
such interference was minimized [18–20]. We utilized the
p19RLC (RPAb) to quantify phosphorylation of RLC at S19 in
subsequent experiments.
One important distinction between the data provided by the
p19RLC and the CtRLC Abs is that the p19RLC data does not
represent a closed system, since it is unable to provide information
about 0pRLC or phospho-states that do not include phospho-S19.
Therefore, the use of p19RLC Ab in this setting cannot assess
quantitative changes in phospho-states, but can provide informa-
tion about whether the proportions of phosphoisotypes (containing
phospho-S19-RLC) within each phospho-state have changed. In
Figure 5C, the y-axis corresponds to the proportion of the in-lane
signal that is made up by 1pRLC
19 or 2pRLC
19 relative to their
sum (i.e. [signal 1pRLC
19]/([signal 1pRLC
19]+[signal 2pRLC
19]),
etc.). For numerical data, see Table 2.
In the untreated group, the relative proportions of 1pRLC
19
and 2pRLC
19 are 6063% and 4063%, respectively. g-H
treatment causes a shift in these proportions to 9167% and
964%, suggesting that ROK inhibition causes specific loss of
2pRLC containing phospho-S19-RLC. However, the data pro-
vided earlier in Figure 3D clarify that both 1pRLC and 2pRLC
are markedly reduced with g-H. In contrast, Calp changes the
weighting of 1pRLC
19 and 2pRLC
19 to 4366% and 5765%,
respectively, reflecting the specific enhancement in 2pRLC seen in
Figures 2 and 3D. The corresponding values for OT are 5464%
and 4665% indicating that OT induces both 1pRLC
19 and
2pRLC
19 to a similar extent, even if the total cellular content of
1pRLC is larger, as evidenced by the data in Figure 3D.
MLCK and ROK Contribute to OT- and Calp-induced
changes in Phosphorylation of RLC
By applying the above methods, we next evaluated the changes
in phosphorylation of RLC that occur upon stimulation with OT
and Calp treatments in the presence of cell-permeable inhibitors of
ROK and MLCK (g-H and ML7 [34], respectively). These data
are compiled in Tables 1 and 2. The data in Table 1 suggest that
MLCK inhibition with ML7 results in a reduced ability of OT and
Calp to cause phosphorylation of RLC, evidenced by reduced
levels of 1pRLC
T and 2pRLC
T relative to OT alone, and reduced
2pRLC
T synthesis relative to Calp alone. Interestingly, ROK
inhibition with g-H appears to completely abolish the ability of
Figure 4. Validation of phospho-state data quantification using
a loading control. A. WB for a-actin after traditional and Mn
2+-phos-
tag SDS-PAGE separation of proteins in lysates from uterine myocytes.
In both blots, the anti-a-actin Ab recognizes only a single band. B. Each
band in panel B was first normalized for a-actin, then corrected for the
vehicle. The data are shown as fold-changes relative to vehicle for g-H
(1 mM), Calp (0.5 mU/mL), OT (100 nM). All data are shown as means 6
SEMs (n=4 in all groups).
doi:10.1371/journal.pone.0020903.g004
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T. In the case of OT+g-H, the
reduced 2pRLC
T is accompanied by an accumulation of 1pRLC
T
relative to OT alone. In contrast, the effect of g-H on Calp has
little to no effect on 1pRLC
T, but results in an accumulation of
0pRLC
T relative to Calp alone. These data suggest that the
mechanisms utilized by OT and Calp to enhance phospho-RLC
concentrations are different. However, both stimulants utilize
ROK to induce 2pRLC
T. The data in Table 2 suggest that ML7
does not affect the relative proportion of phospho-S19-RLC
isotypes stimulable by OT or Calp, However, in agreement with
Table 1, g-H causes a loss of 2pRLC
19 relative to 1pRLC
19.
Phosphorylation of Serine-1 of RLC is inducible by
Phorbol Esters
In addition to S19- and T18/S19-modified phosphoisotypes for
RLC, other phospho-sites located at both the N- and C-termini of
RLC have been discovered in vitro [18–20]. These findings give rise
to the possibility of phospho-states greater than 2pRLC [36].
However, the data presented here thus far (Figures 1 and 3) and
other published evidence suggest that only three phospho-states
exist. ([5,9,21,22,37]) Previous biochemical evidence from turkey
gizzard SM suggested that protein kinase C (PKC) was capable of
phosphorylating S1, S2, or T9 of RLC [20,38–40]. Furthermore,
phosphorylation of the PKC target sites prevented subsequent
MLCK phosphorylation of RLC at S19, and vice versa. In
addition, they demonstrated a reduction in the actin-activated
myosin ATPase activity upon phosphorylation of RLC by PKC.
Thus, PKC-mediated phosphorylation of RLC might impact
myocyte function. To assess whether these changes occurred in
human uterine myocytes, we studied the effects of phorbol-12-
myristate-13-acetate (PMA), a PKC activator, on the phospho-
state distribution of RLC. Surprisingly, we identified additional
phospho-states for RLC that correspond to phosphorylation sites
distinct from T18 or S19.
Figure 6A demonstrates the separation of lysates treated with
PMA (1 mM, 30 min) by Mn
2+-phos-tag SDS-PAGE. We noted
the appearance of three bands in at positions slightly above those
we previously identified as 0pRLC, 1pRLC and 2pRLC, such that
the CtRLC Ab cross-reacted with six distinct bands. We
hypothesized that these unidentified bands might correspond to
phosphoisotypes of RLC that exhibit altered mobility in the Mn
2+-
phos-tag matrix. As such, these bands might represent 1pRLC,
2pRLC, and 3pRLC corresponding to phosphoisotypes modified
at a site other than T18 or S19. However, without knowledge of
the specific phosphoisotypes corresponding to these intermediate
bands, the quantitative information provided by the preceding
analysis is difficult to interpret. Thus, instead we turned our
attention to identifying a candidate phosphorylation site that
might account for these additional phosphoisotypes.
We used an Ab directed toward phospho-S1-RLC (p1RLC) to
determine if phosphorylation at S1 was inducible by PMA.
Figure 6B shows WB data that confirms the induction of p1RLC
with PMA, and is not affected by additional OT stimulation. We
used the in-cell western assay to demonstrate (Figure 6C) that
PMA induction of p1RLC is concentration-dependent, suggesting
activation of intracellular signalling systems. Further, to distinguish
Figure 5. Demonstration of Phospho-S19-RLC phospho-state
distribution in uterine myocytes. A. Detection of 0pRLC, 1pRLC
and 2pRLC separated by Mn
2+-phos-tag SDS-PAGE with an Ab toward
the C-terminus of RLC (CtRLC) and two Abs (mouse MonoclonalAb
[MMAb] and rabbit PolyclonalAb [RPAb]) directed toward phospho-S19-
RLC. B. Representative WB demonstrating RLC phospho-states sepa-
rated by Mn
2+-phos-tag SDS-PAGE and probed using PRAb from panel
A. Uterine myocytes were lysed and total protein was harvested after
the following treatments: untreated, or treated with g-H, Calp, OT, or
with their corresponding vehicles. C. Vehicle-corrected distribution data
for 1pRLC
19 and 2pRLC
19 obtained by normalizing the data in panel A
to the untreated group distribution. g-H (1 mM, n=5). Calp (0.5 mU/mL,
n=10). OT (100 nM, n=10). All data are shown as means 6 SEMs. The
corresponding numerical data are compiled in Table 2.
doi:10.1371/journal.pone.0020903.g005
Table 2. Changes in Relative Proportions of Phospho-S19-
RLC Isotypes in uterine myocytes.
% of phospho-S19-RLC
N 1pRLC 2pRLC
Untreated 12 60634 0 63
g-H (1 mM) 5 9167** 964***
OT (100 nM) 10 54644 6 65
OT+g-H 4 62610 39615
OT+ML7 (25 mM) 6 62633 39622
OT+ML7+g-H 6 7163** 2964
Calp (0.5 mU/mL) 10 4366** 5765
Calp+g-H 2 77612 3 61
Calp+ML7 4 55644 5 64
Calp+ML7+g-H 3 57654 3 65
All data are shown as mean 6 SEM.
** and ***indicate significant differences (p,0.05) compared to 1pRLC and
2pRLC in the untreated group, respectively.
doi:10.1371/journal.pone.0020903.t002
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properties of phorbol esters, we selected 4-a-PMA as negative
control since this agent is ineffective at activating PKCs [41]. As
shown in Figure 6C, treatment with 4-a-PMA did not result in
increased concentrations of p1RLC, confirming the specificity of
the PMA treatment.
Thus far, we have focused on the alkaline Mn
2+-phos-tag
method. Subsequent attempts to improve resolution of the
unidentified bands from 0pRLC, 1pRLC and 2pRLC by Mn
2+-
phos-tag were inconsistent. Recently, an improved method of
separation using Zn
2+ instead of Mn
2+ ions in the phos-tag matrix
and an alternate buffer set for electrophoresis was developed [42].
We used this advanced Zn
2+-phos-tag method to study the PMA-
induced changes in the RLC phospho-states. In order to detect as
many phospho-states as possible, we studied the effects of PMA
and of the protein phosphatase 1 and 2A inhibitor, calyculin A. To
elucidate the phosphoisotypes contained within each phospho-
state, we used the MMAb directed toward p19RLC since it is
detected independently using a secondary Ab directed towards
murine primary Ab whereas the CtRLC and p1RLC (both
RPAbs) are detected using a secondary Ab directed towards rabbit
polyclonal Abs. Figure 7A demonstrates that the CtRLC Ab
recognizes more than 3 bands in the presence of PMA, whereas
phosphatase inhibition with calyculin A enhances 1pRLC and
2pRLC, but does not create any additional phospho-states. When
uterine myocytes are challenged with both PMA and calyculin A,
a band corresponding to a 3pRLC state can be discerned, and
most likely corresponds to RLC phosphorylated at S1, T18, and
S19. Figure 7B shows that the intermediate bands produced by
PMA with or without calyculin A contain p1RLC, and suggests
that phosphoisotypes of RLC containing phospho-S1 move more
rapidly through the phos-tag matrices than those containing
phospho-S19 with equivalent phosphate stoichiometries. They also
suggest that there exists a 3pRLC state corresponding to phospho-
S1/T18/S19-RLC that is inducible with PMA treatment. Thus, it
appears that S1, T18, and T19 can exist simultaneously, rather
than in mutual exclusivity to one another. However, we cannot
exclude the possibility that sites other than S1, T18, and S19 have
been induced by PMA, in the absence of other phospho-site-
specific Abs. To clarify this possibility, future studies might benefit
from the use of phos-tag SDS-PAGE in combination with other
techniques such as mass spectrometry [43].
Physiological Relevance of RLC Phospho-state
Distribution Measurements
In the present work, we treated three phospho-states of RLC as
a closed system based on strong evidence that other states are
unlikely to exist physiologically. This rationale is in agreement
with our data (Figures 1,3–5) and with studies performed in rat
uteri demonstrating the three phospho-states for RLC (0pRLC,
1pRLC, and 2pRLC) as determined by two-dimensional analyses
[23,25]. Our results also agree with kinetic data regarding MLCK
activity suggesting the potential for phosphorylation of nearly the
whole pool of RLC during a physiological stimulus [25]. In
particular, OT was shown to induce phosphorylation in
approximately 80% of the pool of RLC molecules available in
rat uterus [25] compared to .90% phosphorylation in our data.
In contrast, it appears that a much smaller portion of the RLC
pool is phosphorylated at rest in vascular SM [5]. Further, in OT-
stimulated uterine myocytes from rats it appears that dipho-
sphorylation is quantitatively more prominent than monopho-
sphorylation [24]. Our data suggest that human uterine myocytes
might respond similarly to OT with respect to mono- and
diphosphorylation of RLC at S19. This validated methodology
can be used to explore potentially significant differences between
experimental conditions, and is likely also applicable to studying
tissue differences. This type of information could be of key
importance in the design of pharmacological agents that will have
specificity for a single tissue or a specific physiological situation.
In our early experiments, we assumed that all phosphoisotypes
with equivalent phosphate stoichiometries comigrate in the phos-
tag acrylamide matrix. However, the data in Figures 6 and 7
suggest this assumption is incorrect. Under some experimental
conditions, some phosphoisotypes might exist that do not conform
to these migration characteristics. We demonstrated that phos-
phoisotypes corresponding to p1RLC exhibit altered mobility in
Figure 6. PMA induces phosphorylation of RLC at S1 and alters mobility of phospho-RLC during phos-tag SDS-PAGE. A. WBs
produced by Mn
2+-phos-tag separation of lysates from uterine myocytes treated with PMA (1 mM) or vehicle. The membranes were probed with an
Ab directed against the C- terminus of total-RLC (CtRLC). 0pRLC, 1pRLC, and 2pRLC correspond to non-, mono-, and di-phosphorylated RLC. The
bands labeled with ** exhibit unexpected mobility in the Mn
2+-phos-tag acrylamide matrix. B. Traditional WBs demonstrating phosphorylation of RLC
at S1 (p1RLC) in uterine myocytes treated with PMA. C. Quantification of p1RLC concentrations in uterine myocytes treated with PMA and 4-a-PMA
(negative control) by the in-cell western method. In B and C, the data represent 4 independent experiments and are presented as means 6 SEM.
doi:10.1371/journal.pone.0020903.g006
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might facilitate further biochemical characterization of these
phosphoisotypes.
Some in vitro data suggest that PKC-mediated phosphorylation
of RLC results in reduced myosin ATPase activity and impaired
S19 phosphorylation by MLCK [18–20,39,44]. However, subse-
quent experiments using an in vitro motility assay for myosins
isolated from various sources demonstrated that PKC phosphor-
ylation of RLC could not induce movement of myosin beads along
actin cables on its own, and also did not alter the rate of movement
of the myosin beads after MLCK-mediated phosphorylation of
RLC [45]. However, the majority of available data regarding
PKC actions on RLC are often irreconcilable regarding the
specific site(s) of action and subsequent physiological relevance.
The inconsistencies might stem from differences in model species
and experimental approaches. Whatever the source of variability,
the utility of PKC-mediated phosphorylation of RLC for
therapeutic use in humans remains unclear. The p1RLC
phosphoisotypes inducible by PMA (Figure 7) appear to make
up only a small proportion of the total RLC signal present. Co-
incubation of PMA with calyculin A appears to improve the
incorporation of p1RLC into a greater proportion of the RLC
pool, but it is unclear whether these pharmacologic manipulations
are of any physiological significance. Still, it is interesting that
p1RLC is inducible in intact myocytes, suggesting the presence of
an intact signalling system aimed at phosphorylating a poorly
characterized phospho-site on RLC. In the interest of uncovering
novel therapeutic strategies for reducing smooth muscle contrac-
tility, this finding warrants further study.
Materials and Methods
Ethics Statement
The protocol to obtain biopsies from the lower segment of the
uterus at the time of cesarean section was reviewed and approved
by the Human Ethics Review Board of the University of Alberta
and the Ethics Review Board of Alberta Health Services, the
provider of healthcare services in the region. A research nurse at
the Royal Alexandra Hospital in Edmonton obtained informed
and written consent from each patient.
Primary Myometrial Cell Cultures
This methodology has been detailed previously [9]. Briefly,
Myometrial biopsies were obtained from the lower segment of the
uterus from non-laboring patients at term (37–40 weeks) gestation
during elective caesarean section. Biopsies were diced then
incubated in HBSS (Gibco, (Invitrogen, Carlsbad, CA)) containing
1% antimycotic/antibiotic (Gibco), 2 mg/mL collagenase (Sigma-
Aldrich, St. Louis, MO), and 200 ng/mL DNase I (Roche, Laval,
QC) in a total volume of 10 mL for 1 hr at 37uC with shaking. After
1 h, the debris was allowed to settle, the supernatant discarded, and
the remaining tissue was incubated in 10 mL of freshly prepared
Figure 7. Advanced phos-tag analysis of phosphorylated RLC in PMA-treated uterine myocytes. A and B. WBs produced by Zn
2+-phos-
tag (40 mM) separation of lysates from untreated samples, or samples treated with PMA (1 mM), CalyculinA (20 nM), or with both. In both A and B, the
red signal corresponds to a mouse monoclonal Ab (MMAb) targeting p19RLC that is detected independently of the green signals (CtRLC in panel A,
and p1RLC in panel B). A yellow signal indicates overlap of the individual green and red signals. 0pRLC, 1pRLC, 2pRLC and 3pRLC denote non-, mono-,
di-, and tri-phosphorylated RLC. The superscripts denote the position of the phospho-modification: 1: S1, 18: T18, 19: S19. The unlabeled arrow below
3pRLC
1/18/19 corresponds to 2pRLC
18/19 that is particularly prominent in lysates treated with CalyculinA alone.
doi:10.1371/journal.pone.0020903.g007
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dispersed cell mixture was filtered through a 100-mm cell strainer,
centrifuged at 20006g for 5 min, and washed twice with PBS.
Isolated uterine myocytes were grown in DMEM (Gibco)
supplemented with 10% FBS (Gibco) and 1% antimycotic/
antibiotic (Gibco) at 37uC in humidified 5% CO2/95% air. Cell
cultures were grown to 80–100% confluence in a single well of a 6-
well plate post-isolation, then in T25 and T75 flasks (Ultident, St.
Laurent, QC). Prior to experiments, the myocytes are seeded at 600
cells/mm
2 in 6-well plates and allowed to adhere and equilibrate
O/N. The next morning, the cells were washed once with pre-
warmed DMEM containing no additives, and then placed into the
incubator in DMEM without additives for 2–4 hrs before
treatment. All stimulants, pharmacologic agents, and drug diluents
(DMSO,DMF,and H2O)weredilutedinDMEMwithoutadditives
to the final concentration prior to experiments. Oxytocin (1 mM,
sterile ddH2O), glycyl-H-1152 (g-H, 5 mM, DMSO), ML7 (5 mM,
DMSO), and phorbol-12-myristate-13-acetate (PMA, 10 mM,
DMSO) were obtained from Calbiochem (EMD Chemicals,
Gibbstown, NJ, USA). 4-a-PMA (10 mM, DMSO) was purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Calpeptin (Calp, 400 mU/mL, DMF) and the cell permeable rhoA
inhibitor (C3 transferase, 1 mg/mL, H2O) were purchased from
Cytoskeleton, Inc (Denver, CO, USA). Calyculin A (200 mM,
DMSO) was purchased from Cell Signaling (Beverly, MA, USA).
Uterine myocytes were treated for 20 sec with OT, 30 min with g-
H, ML7, PMA, 4-a-PMA, or Calyculin A and 15 min with Calp, as
determined by optimization experiments.
Traditional and Phos-tag SDS-PAGE
Briefly, total cellular proteins were recovered by trichloro-
acetate precipitation (20% TCA and 10 mM DTT in ddH2O),
recovered into microtubes, and centrifuged at 18,000 g for 20 min.
The protein pellets were washed several times with acetone-DTT
(10 mM), allowed to air dry, then resuspended in 75 mLo f1 6
SDS-loading buffer by boiling for 10 min. 15 mL of each sample
was loaded per lane (approximately 25 mg protein/lane) on Tris-
Glycine-SDS minigels. Electrophoresis was carried out by
standard methods, in 15% acrylamide gels. In addition, two
methods of phos-tag (NARD Institute, Ltd., www.phos-tag.
comSDS-PAGE were performed. The first method is described
in [3,9]. We used 30 mMM n
2+-phos-tag in 12% acrylamide gels,
and performed electrophoresis in a manner identical to traditional
SDS-PAGE. The second method of phos-tag SDS-PAGE is
detailed in [42]. In this case, we used 40 mMZ n
2+-phos-tag in 8%
acrylamide gels and performed electrophoresis in the modified
buffer set indicated in [42]. After electrophoresis, the divalent
cations were removed from both types of phos-tag gels by
incubation with transfer buffer containing 2 mM EDTA for
15 min. The gel contents were transferred to nitrocellulose for
1.5 hrs at 100 V by standard methods.
Western Immunoblotting
This methodology has been detailed previously [9]. The blotting
membranes were incubated for 1 hr at R/T in odyssey blocking
buffer (mixed 1:1 with PBS), then incubated overnight with
primary Abs diluted in blocking buffer:PBS supplemented with
0.1% Tween-20. The final primary Ab dilutions were: CtRLC
1:1000 (LS-C81207, Rabbit PAb, LifeSpan BioSciences, Seattle,
WA, USA), p19RLC 1:200 (#3671, Rabbit, PAb, Cell Signaling),
p19RLC 1:2000 (#3675, Mouse, MAb, Cell Signaling),
p18p19RLC 1:500 (#3674, Rabbit, PAb, Cell Signaling),
p1RLC 1:2000 (MP3461, Rabbit, PAb, ECM Biosciences), rhoA
1:200 (#610990, Mouse, MAb, BD Biosci., Mississauga, ON,
Canada), and a-actin 1:4000 (sc-56499, Mouse, MAb, Santa-
Cruz). Secondary Abs conjugated to IRDye 800CW (anti-rabbit,
Li-COR) or Alexa Fluor 680 (anti-mouse, Molecular Probes,
Invitrogen) were diluted in blocking buffer: PBS supplemented
with 0.1% Tween-20 and 0.01% SDS and used at a final dilution
of 1:20,000. Membranes were scanned and analyzed using an
OdysseyH IR (Li-COR) scanner with imaging software version 3.0.
Ab signals were analyzed as integrated intensities of regions
defined around the bands of interest.
In-Cell Westerns
This method was described in detail previously [9]. The final
antibody dilutions were: p19RLC 1:1000 (#3675, Mouse MAb,
Cell Signaling), ppRLC 1:500 (#3674, Rabbit PAb, Cell
Signaling), p1RLC 1:2000 (MP3461, Rabbit PAb, ECM Biosci-
ences). An anti-rabbit or anti-mouse secondary Abs (1:1000,
IRDye 800CW, Li-COR) were used for detection. Ab signals were
normalized to cell loading controls (DRAQ5 (1:10,000, Biostatus
Ltd.) and Sapphire700 (1:1000, Li-COR)). Microplates were
scanned and analyzed using an OdysseyH IR scanner using
OdysseyH imaging software version 3.0, with an offset of 4.0 mm.
Results are expressed as percent relative responses (means 6 SEM)
compared to vehicle-treated controls.
Measurement of RhoA Activity by G-LISA
Relative rhoA activity was estimated by a commercially
available ELISA-based assay (‘G-LISA
TM’, BK-124, Cytoskeleton
Inc.) according to the manufacturers’ specifications. Briefly,
uterine myocytes were treated with 0.5 mU/mL Calp for
15 min, and then harvested by lysis in ice-cold buffer (provided).
An aliquot of these samples was retained for protein content
estimation by ADV02 reagent (Cytoskeleton, Inc.), and the rest
was flash frozen in N2(l), and stored at 280uC until needed. The
frozen samples were thawed and prepared for the assay as
specified. Approximately 25–30 mg total protein was used per well,
and each sample was assayed in duplicate. The measured optical
density measured at 490 nm was expressed relative to vehicle
control. These data were normalized for total-rhoA content by
performing WB analysis in parallel with the rhoA activity assay.
Preliminary experiments comparing uterine myocyte lysates to
purified, constitutively active rhoA (G14V) positive controls
demonstrated that our measurements were within the linear range
of the assay.
Statistical Analysis
All results were expressed using means 6 S.E.M. In-cell western
data were analyzed using one-way ANOVA, followed by a post-
hoc Tukey test. Two-tailed independent t-tests were used to
analyze rhoA activation and WB data, and phospho-RLC
proportion data in Tables 1 and 2. A p-value,0.05 was used to
establish statistical significance.
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